The Cleaved Cytoplasmic Tail of Polycystin-1 Regulates Src-Dependent STAT3 Activation

Jeffrey J. Talbot,* Xuewen Song,† Xiaofang Wang,‡ Markus M. Rinschen,§ Nicholas Doerr,* Wells B. LaRiviere,‡ Bernhard Schermer,§¶ York P. Pei,† Vicente E. Torres,‡ and Thomas Weimbs*

*Department of Molecular, Cellular, and Developmental Biology, and Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California; †Divisions of Nephrology and Genomic Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada; ‡Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; §Department II of Internal Medicine and Center for Molecular Medicine Cologne, Cologne, Germany; ¶Systems Biology of Aging Cologne (Sybacol), Cologne, Germany; and ¶Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany

ABSTRACT
Polycystin-1 (PC1) mutations result in proliferative renal cyst growth and progression to renal failure in autosomal dominant polycystic kidney disease (ADPKD). The transcription factor STAT3 (signal transducer and activator of transcription 3) was shown to be activated in cyst-lining cells in ADPKD and PKD mouse models and may drive renal cyst growth, but the mechanisms leading to persistent STAT3 activation are unknown. A proteolytic fragment of PC1 corresponding to the cytoplasmic tail, PC1-p30, is overexpressed in ADPKD. Here, we show that PC1-p30 interacts with the nonreceptor tyrosine kinase Src, resulting in Src-dependent activation of STAT3 by tyrosine phosphorylation. The PC1-p30-mediated activation of Src/STAT3 was independent of JAK family kinases and insensitive to the STAT3 inhibitor suppressor of cytokine signaling 3. Signaling by the EGF receptor (EGFR) or cAMP amplified the activation of Src/STAT3 by PC1-p30. Expression of PC1-p30 changed the cellular response to cAMP signaling. In the absence of PC1-p30, cAMP dampened EGFR- or IL-6–dependent activation of STAT3; in the presence of PC1-p30, cAMP amplified Src-dependent activation of STAT3. In the polycystic kidney (PCK) rat model, activation of STAT3 in renal cystic cells depended on vasopressin receptor 2 (V2R) signaling, which increased cAMP levels. Genetic inhibition of vasopressin expression or treatment with a pharmacologic V2R inhibitor strongly suppressed STAT3 activation and reduced renal cyst growth. These results suggest that PC1, via its cleaved cytoplasmic tail, integrates signaling inputs from EGFR and cAMP, resulting in Src-dependent activation of STAT3 and a proliferative response.


Autosomal dominant polycystic kidney disease (ADPKD) is a common, life-threatening genetic disease characterized by the progressive growth of renal cysts that eventually destroy the normal tissue architecture, leading to renal failure.1–3 There is currently no approved treatment to slow disease progression, and most patients eventually require dialysis or kidney transplantation. Renal cysts originate from tubule epithelial cells; cystic expansion is driven by proliferation and fluid secretion and is accompanied by fibrosis and excessive extracellular matrix deposition. Germline mutations in the genes encoding polycystin (PC) 1 or PC2, PKD1 and PKD2, respectively, are the root cause underlying ADPKD.
with PKD1 mutations accounting for most cases. The normal functions of PC1 and PC2 are not well understood, but both proteins have been implicated in the regulation of numerous signaling molecules and pathways. In particular, PC1—a large multispanning membrane protein—has been shown to regulate heterotrimeric G proteins, mammalian target of rapamycin, STAT (signal transducer and activator of transcription 3) transcription factors, wnt signaling, and several other pathways. However, the exact molecular mechanisms that are involved, the purpose of their regulation, and the importance to renal cyst growth are still largely unclear.

We have recently shown that PC1 regulates the activity of the transcription factor STAT3 by a unique dual mechanism. PC1 can directly activate STAT3 by tyrosine phosphorylation due to its physical interaction with the tyrosine kinase Janus kinase 2 (JAK2). In addition, PC1 can also undergo proteolytic cleavage, which releases its cytoplasmic tail from the membrane. This soluble C-terminal fragment, termed PC1-p30, has lost the ability to directly activate STAT3 by JAK2-mediated phosphorylation but instead undergoes nuclear translocation, interacts with transcriptional coactivators, and can coactivate STAT3-dependent gene expression. We and others have shown that STAT3 is very strongly activated by tyrosine-phosphorylation in cyst-lining cells in ADPKD and several mouse models. Moreover, initial attempts to inhibit STAT3 in PKD mouse models have led to reduction of renal cyst growth. These results suggest that the STAT3 pathway could be exploited as a drug target for ADPKD therapy. STAT3 is known to be aberrantly activated in numerous forms of cancer, is a driving force of tumor cell proliferation, and is being pursued as a drug target for cancer therapy. Although PC1 can regulate STAT3 activity, the actual mechanism leading to STAT3 activation in PKD is unknown. Several signaling pathways linked to the pathogenesis of ADPKD are known to signal via STAT3 in other cell types, including epidermal growth factor and EGFR receptor (EGFR), TNF-α, Src, and hepatocyte growth factor/Met. In addition, suppressor of cytokine signaling 3 (SOCS3), an inhibitor of some STAT3 signaling pathways, is overexpressed in hepatocyte nuclear factor (HNF)-1β null mice that develop renal cysts. STAT3 is also activated in renal tubule cells during AKI and plays a critical role in the response to injury. Following AKI, SOCS3 levels are depressed, corresponding with increased STAT3 activity associated with the tubule repair process. Both the loss and overexpression of SOCS3 have been associated with renal disease. Renal injury can trigger rapid cyst growth in pre-conditioned mouse models, and there are numerous parallels between the response to renal injury and the pathogenesis of PKD, which has led to the hypothesis that PKD represents the aberrant, persistent activation of cellular pathways that are normally intended for tissue regeneration.

We hypothesized that another potential link between renal cyst growth and STAT3 signaling may be aberrant cAMP signaling. Excessive cAMP levels may drive cyst fluid secretion and proliferation, and they appear to be largely due to aberrant vasopressin receptor 2 (V2R) activation. Cyst epithelial cells respond to increased cAMP by increased proliferation, whereas normal renal tubule cells do not. Inhibition of V2R signaling mitigates cyst growth in PKD animal models, and a recent phase 3 clinical trial showed beneficial effects of the V2R inhibitor tolvaptan in patients with ADPKD. Transformation of cancer cells by constitutively active G-α proteins involves Src-dependent STAT3 activation. Part of this mechanism may involve cAMP signaling because the CAMP-dependent kinase protein kinase A (PKA) has been shown to phosphorylate and activate Src.

To understand the mechanisms underlying aberrant STAT3 activation in PKD, we have investigated the regulation of STAT3 by PC1. We and others have shown previously that PC1 is overexpressed in cyst-lining cells in ADPKD and mouse models and is proteolytically cleaved, which leads to accumulation of the nuclear-targeted cytoplasmic tail. Here, we show that STAT3 is strongly activated in PKD despite highly upregulated expression of SOCS3 indicating that the STAT3-activating mechanism is insensitive to inhibition by SOCS3. We show that direct STAT3 activation by membrane-anchored PC1/JAK2 is inhibited by SOCS3. Instead, the cleaved C-terminal PC1 tail is capable of interacting with Src, which leads to strong STAT3 activation in a mechanism that is insensitive to SOCS3. This pathway is amplified by both EGFR activation and by increased cAMP. These results suggest a model in which the cleaved PC1 tail integrates inputs from EGFR, Src, and cAMP signaling pathways to activate STAT3 while bypassing inhibition by SOCS3.

RESULTS

Regulation of STAT3 Activity and SOCS3 Expression in Renal Epithelial Cells and ADPKD

Aberrant STAT3 activation in PKD may be due to abnormal growth factor signaling or intrinsic STAT3 regulation. To test whether renal epithelial cells can regulate STAT3 activity intrinsically in the absence of changes in the growth factor environment, we assessed the level of STAT3 activation as they differentiate— as they differentiate into a well organized, postmitotic monolayer. Previous gene expression results indicated that SOCS3 expression is increased in cyst-lining cells in ADPKD compared with normal kidneys. To confirm and quantify this, we analyzed SOCS3 expression in an expanded sample set of isolated

human PKD1 cysts versus control tissues. SOCS3 expression is indeed greatly increased in PKD1 cysts (Figure 1C). These results suggest that the mechanism causing high-level STAT3 activation in PKD may be insensitive to inhibition by SOCS3.

**JAK2-Dependent STAT3 Activation by Membrane-Anchored PC1 Is Inhibited by SOCS3**

We tested whether the previously described PC1/JAK2-dependent activation of STAT3 is sensitive to SOCS3 inhibition. Overexpression of SOCS3 completely inhibits the activation of STAT3 by full-length PC1 (Figure 2A) or by a chimeric membrane-anchored construct containing the C-terminal cytoplasmic tail of PC1 (full length membrane-bound tail of PC1 [FLM-PC1]; Figure 2B, Supplemental Figure 2). We tested whether any of the four tyrosine residues present in the cytoplasmic tail of PC1 are required for SOCS3-sensitive STAT3 activation. Loss of all four tyrosine residues (FLM-4Y/F-PC1) does not eliminate the ability of PC1 to activate STAT3 (Figure 2B), and SOCS3 still inhibits this activity. Together, these results indicate that PC1/JAK2-dependent activation of STAT3 is sensitive to SOCS3 inhibition and that the inhibitory effect of SOCS3 probably occurs by direct interaction with JAK2 as opposed to interaction with phospho-tyrosines in PC1.

Intracellular cAMP levels are commonly elevated in cysts in PKD. In other cell types, increased cAMP levels have been
shown to lead to exchange protein activated by cAMP (EPAC)-
dependent stimulation of SOCS3 expression,29,30 which
would be expected to lead to inhibition of JAK2-dependent
STAT3 activation. We found that treatment with the adenylate
cyclase activator forskolin strongly inhibits STAT3 activation
that is mediated by IL6 or by the membrane-anchored PC1 tail
(Figure 2C), both of which signal via JAK.

Altogether, these results suggest that the high levels of cAMP
and SOCS3 in renal cystic cells should be expected to suppress
JAK-dependent activation of STAT3. However, because STAT3
is clearly strongly activated in PKD,4,7,8 this suggests that
STAT3 activation in PKD is mediated by a JAK-independent
pathway. To directly test this, we investigated the levels of ac-
tivated JAK2 (P-Tyr1007/1008) in two PKD mouse models. As
shown in Figure 2D, phospho-JAK2 levels are not increased in
polycystic kidneys compared with controls but rather appear
to be suppressed. This indicates that STAT3 activation in PKD
does not occur via a JAK2-dependent, SOCS3-sensitive path-
way but must be caused by a different mechanism.

The Cleaved, Soluble PC1 Tail Interacts with Src,
Leading to Strong STAT3 Activation

Because activation of STAT3 by membrane-anchored PC1 strictly
depends on JAK2,4 it is unlikely to play a role in the observed
STAT3 activation in PKD. The nonreceptor tyrosine kinase Src
has previously been shown to be activated in PKD rodent mod-
els, and its inhibition leads to amelioration of renal cyst
growth.31 Src was proposed to increase cyst cell proliferation
by stimulating the B-Raf/mitogen-activated kinase/ex-
tracellular signal-regulated kinase (ERK) pathway.31 However,
Src is also known to be able to activate STAT3 by direct tyrosine-
phosphorylation,32,33 and its role in PKD could therefore involve
STAT3 activation. To test whether Src is involved in STAT3 ac-
tivation by membrane-anchored PC1, we coexpressed wild-type
Src, kinase-dead Src (K297M),34 or a dominant-negative mutant
of Src (K297M Y529F)35 with FLM-PC1. None of these treat-
ments affected the ability of FLM-PC1 to activate STAT3 (Figure
3A), indicating that this mechanism is Src-independent; this
finding is consistent with its JAK2-dependency.

We next tested whether the regulation of STAT3 activity by
the cleaved, soluble PC1 tail (PC1-p30) may involve Src. Strikingly, coexpression of PC1-p30 with wild-type Src leads to
extremely strong STAT3 activation compared with Src alone,
and this effect depends on the kinase activity of Src (Figure 3B).
We recently identified a C-terminal, approximately 15-kDa
cleavage product of the PC1 tail (PC1-CTp15) that accumu-
lates in ADPKD kidneys in addition to PC1-p30.4 Neither
PC1-CTp15 nor the corresponding N-terminal half of PC1-
p30 alone is sufficient to activate Src, indicating that the entire
cytoplasmic fragment is required (Supplemental Figure 3).

Coimmunoprecipitation experiments indicate that PC1-p30 may activate Src—directly or indirectly (Figure 3C)—which suggests that complex formation is involved in Src-dependent STAT3 activation. We tested a panel
of PC1-p30 constructs containing ADPKD patient mutations.

None of these mutations disrupts the ability of PC1-p30 to
activate Src (Supplemental Figure 4), indicating that any PC1-
p30 expressed in renal cysts in these patients would still be
expected to stimulate Src and STAT3 activity.

Regulation of Src by the Cleaved PC1 Tail

To explore how PC1-p30 may affect the activity of Src, we tested Src
mutations that affect Src’s separate autoinhibitory mechanisms36
(Supplemental Figure 2): PC1-p30 is still capable of further
enhancing the activity of Src (Y529F) about 8-fold (Figure 4A).
Similarly, Src (D99N)37 can still be further activated by PC1-p30
(Figure 4B). These results indicate that the PC1-p30–dependent
activation of Src is not exclusively due to relieving intramolecular autoinhibition mechanisms involving Tyr529 or the SH3 domain.

To test whether recognition of phosphotyrosine residues
by the SH2 domain of Src is involved, we used the Src (R175K)38
mutant (Supplemental Figure 5). The ability of PC1-p30 to
activate Src is significantly inhibited by the R175K mutation
but not completely eliminated (Figure 4C). To test whether phosphotyrosine residues in PC1-p30 may play a role, we mutated all four Tyr residues to Phe (PC1-p30–4Y/F). This prevented Src activation to a similar extent as mutating Src’s SH2 domain in the Src (R175K) mutant (Figure 4C). When the two mutants were combined, it did not lead to any further suppression of Src activation (Figure 4C). The PC1-p30–4Y/F mutant, was, however, much less capable of activating Src (D99N) (Figure 4B). Together, these results suggest that an interaction between phosphotyrosine residues in PC1-p30 and Src’s SH2 domain is not absolutely required but likely plays a role in positively modulating Src activity.

A conserved proline-rich (PXXP) motif in the cytoplasmic tail of PC1 can interact with the SH3 domain of nephrocytin-1. Removal of this PXXP motif (PC1-p30–Δ4262–72), however, did not affect the ability to activate wild-type Src, or the Src (D99N) or Src (R175K) mutants (Figure 4, B and C), suggesting that PC1’s PXXP motif is not critical for Src activation.

Altogether, these results indicate that the activation of Src by PC1-p30 is likely governed by a complex interaction that may depend on an adapter protein and is subsequently regulated by effects involving the SH2 and SH3 domains of Src.

**PC1-p30/Src-Dependent Activation of STAT3 Is Insensitive to SOCS3**

STAT3 can participate both in a positive and negative feedback mechanism by transcriptionally upregulating its own expression and that of its inhibitor SOCS3, respectively. To test whether PC1-p30/Src-dependent activation of STAT3 can regulate both pathways, we used luciferase reporters driven by the native promoters of the STAT3 and SOCS3 genes, respectively. PC1-p30 indeed leads to Src-dependent enhancement of transcription from these native promoters (Supplemental Figure 6).

Next, we tested whether SOCS3 is capable of inhibiting the PC1-p30/Src-dependent activation of STAT3. As shown in Figure 5A, although SOCS3 strongly suppresses the IL-6–mediated activation of STAT3, it is not capable of suppressing the PC1-p30/Src-dependent activation of STAT3. Similarly, the pan-JAK inhibitor pyridone 6 completely inhibits the IL-6–dependent coactivation of STAT3 by PC1-p30 but fails to inhibit the Src/PC1-p30–dependent activation of STAT3 (Figure 5B). Altogether, these results indicate that PC1-p30 can act as an intrinsic Src activator that leads to transcriptional activity of STAT3 in a manner that is independent of JAK and cannot be suppressed by SOCS3. This mechanism would be consistent with the observation of concurrent high levels of STAT3 and SOCS3 expression and high levels of STAT3 activation in cysts in PKD.

**Increased cAMP and EGFR Signaling Both Amplify PC1-p30/Src-Dependent Activation of STAT3**

Next, we investigated pathways that may be upstream regulators of Src/STAT3 in renal cysts. Both EGFR and cAMP signaling pathways are aberrantly activated in PKD and have been reported to affect Src/STAT3 in other cell types. EGFR activation leads to numerous downstream signaling events, including the ability of EGFR to phosphorylate STAT3 via its tyrosine kinase domain. EGFR activation can also lead to rapid recruitment of Src and Src-mediated STAT3 activation. CAMP may inhibit STAT3 activity by EPAC-dependent upregulation of SOCS3 expression. On the other hand, cAMP may increase STAT3 activity by PKA-dependent phosphorylation and activation of Src.

As expected, EGFR expression leads to STAT3 transcriptional activity, which is further enhanced by Src expression (Figure 6A). Strikingly, expression of PC1-p30 alone or in combination with Src dramatically amplifies the EGFR-dependent activation of STAT3 (Figure 6A). Forskolin (FSK)—which increases intracellular CAMP levels—alone does not affect STAT3 activity in human embryonic kidney 293 cells in the absence of Src (Figure 6B). However, FSK dramatically increases the PC1-p30/Src-mediated activation of STAT3 (Figure 6B), which is inhibitable by the PKA inhibitor H89 (Figure 6C). These results suggest that the PKA-mediated phosphorylation of Src leads to full Src activation only in the presence of PC1-p30.

The combination of EGFR and FSK leads to the strongest PC1-p30/Src-mediated activation of STAT3 (Figure 6D). Interestingly, the EGFR-dependent STAT3 activation is suppressed by FSK in the absence of PC1-p30 but is strongly enhanced in the presence of PC1-p30 (Figure 6D). This suggests that EGFR signaling is normally inhibited by cAMP, likely by EPAC-mediated upregulation of SOCS3, but that expression of PC1-p30 overcomes this inhibition by amplifying the EGFR/Src/STAT3 axis.

CAMP levels are thought to be elevated in renal cysts due to aberrant vasopressin V2 receptor (V2R) signaling. To test whether stimulation of the endogenous V2R in untransfected renal epithelial cells leads to Src-dependent STAT3 activation, we used the mpkCCDcl11 collecting duct cell line, which is responsive to the V2R agonist 1-deamino-8-D-arginine vasopressin (dDAVP). Treatment with dDAVP indeed leads to increased tyrosine phosphorylation of STAT3, and this response can be blocked by pretreatment with PP2, a selective inhibitor for Src-family kinases (Figure 6E). Next, we tested whether PC1-p30 expression leads to increased Src-dependent STAT3 activation in response to cAMP in a renal epithelial cell line. MDCK cells, stably expressing PC1-p30 under doxycycline control, were challenged by increasing intracellular cAMP. This leads to significantly increased STAT3 tyrosine phosphorylation, which is further enhanced in the presence of PC1-p30 (Figure 6F). Again, treatment with PP1 prevents this effect, indicating that STAT3 activation is Src-dependent.

Altogether, these results demonstrate that expression of PC1-p30 results in Src-dependent STAT3 activation and that this function is strongly amplified in conditions of elevated cAMP and/or EGFR signaling.

**Pharmacologic and Genetic Inhibition of Vasopressin Signaling Prevents Renal STAT3 Activation In Vivo**

If increased cAMP levels contribute to increased Src-dependent activation of STAT3 in renal cysts, we would expect...
that inhibiting cAMP signaling in a PKD rodent model should also result in inhibition of STAT3 activity. To test this prediction in vivo, we used the polycystic kidney (PCK) rat model, which has previously been shown to exhibit increased cAMP levels.\(^{21}\) STAT3 is strongly activated in renal cysts in this model (Figure 7). Treatment with the V2R antagonist OPC-31260 decreases renal cAMP and leads to inhibition of renal cyst growth in the PCK rat model.\(^{21,23}\) As shown in Figure 7, A and B, treatment of PCK rats with OPC-31260 eliminates STAT3 activation. To confirm that the effect of OPC-31260 on STAT3 activation is due to inhibition of the V2R, we used PCK rats that have been crossed with Brattleboro rats that lack arginine vasopressin (AVP), the ligand of the V2R. As shown previously, PCK AVP\(^{2}\)/\(^{2}\) rats exhibit lower renal cAMP and reduced renal cyst growth.\(^{24}\) As shown in Figure 7, A and B, PCK AVP\(^{2}\)/\(^{2}\) rats exhibit strongly reduced levels of activated STAT3 compared with PCK rats. Treatment of PCK AVP\(^{2}\)/\(^{2}\) rats with dDAVP again leads to strong activation of STAT3 in cyst-lining cells and resumption of cyst growth (Figure 7). Similar to the PCK model, mice with an engineered unstable Pkd2 gene, the orthologous gene to human ADPKD, exhibit aberrantly activated STAT3, and treatment with OPC-31260 eliminates STAT3 activation (Figure 7C). Altogether, these results suggest that increased STAT3 activation is mediated, at least in part, by increased levels of cAMP in renal tubule epithelial cells in vivo and is likely an important factor that drives renal cyst growth.

DISCUSSION

Previous findings by us\(^{4}\) and others\(^{7,8}\) have demonstrated that STAT3 is strongly activated in renal cyst-lining cells in human ADPKD and several PKD mouse models, and suggested that STAT3 is a driving force for cyst growth.\(^{9,11}\) However, the mechanism of STAT3 activation in renal cysts remained unknown. The observation that increased expression of SOCS3, an inhibitor of STAT3 activation, is associated with renal cyst growth in HNF-1\(^{b}\) null mice\(^{12}\) and human ADPKD (Figure 1D) appeared to contradict a role of STAT3 in cyst growth. Moreover, our finding that wild-type, membrane-anchored PC1 can activate STAT3 via JAK2\(^{4}\) might lead to the conclusion that the loss of functional PC1 in patients with ADPKD should lead to diminished STAT3 activity as opposed to the observed increased STAT3 activity. The results presented here help to resolve these apparent contradictions and suggest a model (Figure 7C) for the integration of multiple signaling pathways that converge on the regulation of STAT3 activity in renal cysts.

We demonstrate that the cleaved, cytoplasmic tail of PC1 (PC1-p30) can interact with Src and that this leads to strong mutant (4Y/F) significantly reduce—but does not eliminate—STAT3 activation by Src. This level of activation is not altered by the loss of the PC1-p30 PXXP motif. Error bars are the mean±SEM. WT, wild-type.

**Figure 4.** Characterization of Src activation by PC1-p30. (A–C) Luciferase assays using human embryonic kidney 293T cells transfected with the STAT1/3 luciferase reporter and the indicated genes. (A) PC1-p30 can still further activate the conditionally active Src Y529F mutant, suggesting that regulation of phosphorylation at that residue is the sole mechanism of Src activation by PC1-p30. Lines indicate fold differences between the two conditions being compared. (B) PC1-p30 can also still further activate the conditionally active Src D99N mutant. Removal of a conserved PXXP motif in PC1-p30 (\(4262-4272\)) does not alter Src/STAT3 activation. Loss of all four tyrosines in PC1-p30 (4Y/F) in combination with loss of PXXP-binding motif in Src significantly reduces Src/STAT3 activation. (C) Alone or in combination, mutation of the SH2 domain of Src (R175K) and the PC1-p30 phospho-tyrosine
Src-dependent, and SOCS3-insensitive, activation of STAT3. This pathway is amplified by increased cAMP levels and by EGFR signaling, both of which are associated with renal cyst growth. Our results suggest that Src is the major activator of STAT3 in renal cysts which is consistent with, and supported by, the following.

Aberrant activation of Src has been reported in renal cysts in the Bpk mouse and PCK rat models of PKD, and treatment with the Src inhibitor SKI-606 strongly suppressed renal cyst growth in the Bpk mouse and PCK rat models of PKD, and treatment with the following.

STAT3 in renal cysts which is consistent with, and supported by, growth. Our results suggest that Src is the major activator of EGFR signaling, both of which are associated with renal cyst growth. This pathway is ampliﬁed, and SOCS3-insensitive, activation of STAT3.

Error bars are the mean±SEM.

Figure 5. The PC1-p30/Src/STAT3 pathway is SOCS3- and JAK-independent. Luciferase reporter assays using human embryonic kidney 293T cells transfected with the STAT1/3 luciferase reporter. (A) Expression of SOCS3 inhibits STAT3 activation by IL-6 but has no effect on PC1-P30/Src-mediated STAT3 activation. (B) The pan-JAK inhibitor pyridone 6 (Pyr6) inhibits STAT3 activation by IL-6 but has no effect on PC1-P30/Src-mediated STAT3 activation. Error bars are the mean±SEM.

Src inhibition would have been found to lead to consequent STAT3 inhibition. All of these results indicate that JAK-dependent and SOCS3-inhibitable pathways are unlikely to be major contributors to STAT3 activation in renal cysts.

Paradoxically, both reducing/eliminating the expression of PC1 (by gene knockout or hypomorphic alleles) and overexpression of PC1 lead to renal cyst growth in transgenic mice. ADPKD has traditionally been regarded as resulting from the loss of functional PC1 due to loss of heterozygosity. However, loss of PC1 in inducible Pkd1 knockout mice leads to rapid renal cyst growth only if the gene is ablated during the first 2 weeks of life, while the kidneys are still growing. In contrast, loss of PC1 in mice with mature kidneys has no effect for several months. Kidneys/cysts of patients with ADPKD have consistently been found to overexpress PC1. Moreover, lack of luminal ﬂuid ﬂow leads to cleavage and nuclear accumulation of the cytoplasmic tail of PC1. The cleaved PC1 tail is abundant in cyst-lining cells in human ADPKD, and a PKD mouse model. Increased abundance of the cleaved C-terminal tail of PC1 can be detected in the nuclei of renal epithelial cells from two mouse models with reduced PC2 protein levels (i.e., Pkd2+/− and Pkd2WS2S/WS2S). PC2 appears to regulate the tail cleavage of PC1, but the exact mechanism remains unknown. Overexpression of the cleaved PC1 tail in zebrafish embryos leads to massive pronephric cyst growth. Altogether, these ﬁndings suggest that the cleaved PC1 tail promotes renal cyst growth.

Our ﬁndings reported here suggest that the cleaved PC1 tail can promote renal cyst growth by Src-dependent activation of STAT3. Importantly, the presence of PC1-p30 sensitizes cells to cAMP and EGFR signaling. In the absence of PC1-p30, cAMP suppresses STAT3 activation caused by EGFR signaling (Figure 6C), IL-6 signaling (Figure 2C), or signaling by membrane-anchored PC1 (Figure 2C). Because all of these mechanisms are sensitive to suppression by SOCS3, and because cAMP is known to lead to EPAC-mediated upregulation of SOCS3 expression, we suggest that increased levels of cAMP in normal renal epithelial cells dampen STAT3 signaling in this way. EPAC signaling in response to cAMP agonists has previously been demonstrated in renal epithelial cells. In contrast, in the presence of PC1-p30, increased levels of cAMP lead to STAT3 activation mediated by Src (Figure 6B). Similarly, in the presence of PC1-p30, EGFR/Src-mediated STAT3 activation is ampliﬁed (Figure 6A). A prediction from these results is that cystic epithelial cells that express PC1-p30 should differ from normal tubule epithelial cells (expressing membrane-anchored PC1 but lacking PC1-p30) in their response to cAMP. Indeed, it has long been recognized that cAMP stimulates proliferation in ADPKD cyst cells but has either no
effect or an antiproliferative effect on normal renal tubule epithelial cells.\textsuperscript{19,20} Similarly, ouabain—a hormone that activates EGFR, Src, and mitogen-activated kinase kinase–ERK pathways—stimulates proliferation in ADPKD cyst cells but not in normal renal tubule cells.\textsuperscript{56} Overall, our results suggest that accumulation of the cleaved PC1 tail in renal epithelial cells in ADPKD changes their response to cAMP stimuli. Although normal cells would respond by dampening STAT3 activation via EPAC/SOCS3, ADPKD cells respond to cAMP by activating STAT3 via PKA/PC1-p30/Src, resulting in a proliferative response.

Increased vasopressin/V2R signaling has been identified as a major source of cAMP stimulation leading to renal cyst growth,\textsuperscript{22,24} and treatment with the V2R inhibitor tolvaptan leads to disease amelioration in patients with ADPKD.\textsuperscript{25} Our results show that STAT3 activation strictly corresponds to V2R signaling in the PCK rat model (Figure 7, A–C). This suggests that V2R/cAMP signaling may be largely responsible for STAT3 activation in renal cysts. In turn, the results suggest that STAT3 activation is a major outcome of V2R/cAMP signaling that is likely to drive cells to a proliferative outcome.

The model emerging from our results places Src and PC1-p30 at the convergence point of cAMP and EGFR signaling (Figure 7D). EGFR overexpression, mislocalization, and activation have been reported in human ADPKD and rodent models.\textsuperscript{57} Treatment with EGFR tyrosine kinase inhibitors inhibits renal cyst growth in several PKD rodent models,\textsuperscript{58,59} but not all.\textsuperscript{60} The EGFR and Src interact with each other, Src can phosphorylate multiple tyrosine residues of the EGFR, and both kinases are thought to be able to mutually activate each other.\textsuperscript{61} STAT3 activation in response to EGFR signaling requires Src.\textsuperscript{44,61} In addition to Src/STAT3 signaling, EGFR activation leads to the activation of several signaling pathways, most notably the mitogen-activated protein kinase (MAPK)/ERK pathway. MAPK/ERK activation has also been reported to be responsible for the proliferative effect of cAMP signaling in renal cysts.\textsuperscript{19} Consequently, MAPK/ERK signaling has been thought to be a major driving force of proliferation and cyst growth in PKD. However, pharmacologic inhibition of MAPK/ERK signaling failed to affect renal cyst growth in a Pkd1 mouse model,\textsuperscript{62} raising doubts about the sole importance of this pathway in PKD. Our results suggest that activation of the Src/STAT3 axis—possibly in conjunction with MAPK/ERK signaling—is an important driver of renal cyst growth.

Our studies using several mutant forms of Src and PC1-p30 (Figures 3 and 4) suggest that the regulation of Src activity by...
PC1-p30 is governed by a complex interaction. Tyr4237 in the PC1 tail has been shown to be a substrate of Src in vitro. Mutation of all four tyrosines in PC1-p30 suppresses the ability to fully activate Src (Figure 4). This may suggest that Y-phosphorylation of PC1-p30 by Src plays a role in Src activation, perhaps by stabilizing the interaction between these two proteins. Activation of Src by PC1-p30 appears to only partially involve several known mechanisms of Src regulation: the relieving of intramolecular autoinhibition mechanisms involving Tyr529 and the SH3 domain of Src, and the recognition of phosphotyrosine residues by the SH2 domain of Src (Figure 4).

Overall, our results are consistent with a model of multiple binding interactions in which both the SH2 and SH3 domains of Src bind the phosphotyrosine residues and PXXP motifs of PC1-p30, respectively, allowing it to adopt a maximally open conformation, thus being fully active. The complexity of the interaction also suggests that it may be facilitated by an adaptor protein. It is possible that the interaction of the PC1 tail with Src may also serve to recruit Src to the vicinity of other targets. In this regard, NPHP1—a protein mutated in the renal cystic disease nephronophthisis—binds via its SH3 domain with the PXXP motif in the PC1 tail. Because NPHP1 has been shown to be phosphorylated by Src, it is possible that Src acts on the complex of PC1 and NPHP1. In addition, EGFR interacts with the C-terminal part of the cytoplasmic tail of PC2, the same domain that interacts with the PC1 tail. Furthermore, PC1-mediated Src activity may be regulated by receptor protein tyrosine phosphatases because receptor-type tyrosine-protein phosphatase-γ has been shown to interact with the PC1 tail and to dephosphorylate the Src phosphorylated residue, Y4237.

What is the physiologic role of the PC1-p30/Src/STAT3 pathway identified here? Numerous similarities exist in the activation of signaling pathways and biologic responses between PKD kidneys and kidneys that respond to insults such as ischemia reperfusion injury and obstruction. This has led to the hypothesis that the pathogenesis of PKD involves the aberrant activation of innate renal response mechanisms to insults that normally serve the purposes of tissue regeneration and defense against pathogens. Indeed, Src is activated in tubule epithelial cells in response to ischemia reperfusion injury and appears to participate in tubular regeneration. PC1 expression is increased after renal ischemia reperfusion injury, and the cleaved PC1 tail accumulates in tubule epithelial cells in response to ureteral obstruction. Therefore, we speculate that the PC1-p30/Src/STAT3 pathway is normally activated in response to renal insults and integrates signaling inputs (such as EGF and cAMP) to provide a proliferative outcome to facilitate tissue regeneration. Constitutive activation of this pathway in ADPKD would lead to aberrant proliferation of renal epithelial cells and cyst growth. Because Src/STAT3 lie at the converging point of numerous signaling pathways implicated in PKD, their inhibition appears to be a promising therapeutic avenue to pursue.

Figure 7. Pharmacologic or genetic inhibition of vasopressin/V2R signaling in vivo inhibits STAT3 activation and renal cyst growth. (A and B) Immunohistochemistry (A) or immunoblot (B) of wild-type (WT) and PCK rat kidney sections, and kidney lysates, respectively. Animals were treated with vehicle alone, the V2R-inhibitor OPC31260, or dDAVP as indicated. Wild-type rats, PCK rats, or PCK rats crossed with Brattleboro rats (AVP−/−) are compared. (C) Pkd2W52S/− or control mouse were similarly treated with or without OPC31260 or vehicle. (D) Model depicting pathways activated in PKD disease in which PC1-p30 acts as an activator of Src. This results in driving EGFR and cAMP signaling toward Src-dependent STAT3 activation in a manner that is independent of SOCS3.
CONCISE METHODS

SOC3 mRNA Expression Analysis
Semi-quantitative RT-PCR was done using total RNA from MDCK cells. Microarray and quantitative PCR analyses from human tissues were performed as previously described.28 For the complete methods, see the Supplemental Information.

Luciferase Transcriptional Reporter Assays
Luciferase reporter assays were carried out in triplicate in human embryonic kidney 293T cells as previously described.4 All experiments were repeated at least three times, and representative experiments are shown.

Plasmids
cDNAs of membrane-anchored and soluble PC1 constructs in pCDNA4/TO have been described previously,4,5,69 and additional mutated constructs were made by site-directed mutagenesis. The following plasmids were kindly provided by the following: full-length PC1 (G. Germino, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD); STAT1/3 luciferase reporter4 (T. Hamilton, Cleveland Clinic, Cleveland, OH); luciferase reporters containing native STAT3 and SOCS3 promoter regions70 (G. Stark, Cleveland Clinic); EGFR (D. Wheeler, University of Wisconsin, Madison, WI); SOCS3 71 Addgene plasmid 11486 (R. Kahn, Harvard Medical School, Boston, MA); and wild-type c-Src (Addgene plasmid 13663; J. Brugge, Harvard Medical School). Kinase dead (K297M), dominant negative (K297M Y529F), constitutively active (Y529F), SH2-binding (R175K), and SH3-binding (D99N) mutants of Src were all made on the same pCMV5 backbone using site-directed mutagenesis.

Rodent Models
Animal studies were approved by the Institutional Animal Care and Use Committees and adhered to the National Institutes of Guide for the Care and Use of Laboratory Animals. The bkp and Pkd1cond/cond; NestinCre mice models have been described previously.4,69,72–74 PCK rats and crossed PCK/Brattleboro rats have been described previously.4

OPC31260 was administered by dying to Chow at a concentration of 0.1% between 3 and 10 weeks of age. dDAVP was administered via osmotic minipumps (Alzet, CA) at a dose of 10 ng/hr per 100 g body weight between 3 and 10 weeks of age.

ACKNOWLEDGMENTS
This study was supported by grants DK62338 (to T.W.), DK44863 and DK090728 (to V.T) from the National Institutes of Health, and MOP77806 from Canadian Institutes of Health Research (to Y.P.). M.M.R. was supported by an intramural scholarship from the University of Cologne (Koeln-Fortune).

DISCLOSURES
None.

REFERENCES


This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2013091026/-/DCSupplemental.
Supplemental Information

Complete Materials and Methods

**SOCS3 mRNA expression analysis**
Total RNA was isolated from MDCK cells using the RNeasy kit (Qiagen) according to the manufacturers protocol. Semi-quantitative RT-PCR of SOCS3 was carried out with normalized RNA levels using the ImProm-II Reverse Transcription System (Promega). Microarray and qPCR from normal and ADPKD human tissues were performed as previously described. Renal cysts of different sizes were obtained from five polycystic kidneys removed for medical reasons. Small cysts (SC) were defined as less than 1 ml, medium cysts (MC) between 10 and 25 ml and large cysts (LC) greater than 50 ml. Minimally cystic tissues (MCT), which might have contained a few microscopic cysts from the renal cortex, was obtained as PKD control tissue from the same kidneys. Additionally, non-cancerous renal cortical tissue from three nephrectomized kidneys with isolated renal cell carcinoma was used as normal control tissue. As described previously, using the top 200, 500, 1000 or 2000 most variable genes across all samples in an unsupervised hierarchical cluster analysis, all cyst samples consistently clustered as a single group, while the MCT and normal renal cortical samples clustered as a second group. These results suggest that the gene expression pattern is very similar between renal cysts, albeit of different sizes, and between MCT and normal renal cortical tissue.

**Luciferase transcriptional reporter assays**
HEK293T cells were cultured overnight on 12-well plates and transfected with plasmids containing the luciferase reporter (0.25 μg), β-galactosidase (10 ng), and the gene of interest (0.25 μg). Plasmids amounts were balanced with pEGFP plasmid (Clontech). Cells were transfected with Lipofectamine2000 in OptiMEM (Invitrogen) according to manufacturer’s protocol, and cultured in normal medium. Growth factors/cytokines were added post-transfection for at least 16 hrs prior to lysis. Approximately 24 hrs post-transfection cell lysates were assayed for luciferase and β-galactosidase activity. Luciferase units were normalized using β-galactosidase. Experimental conditions were assayed in triplicate, each bar represents average mean fold induction with respect to control. Error bars represent standard error of the mean. All experiments were repeated at least three times and representative experiments are shown.

**Co-precipitation binding assay**
HEK293T cells were cotransfected with Src and glutathione-S-transferase (GST) or a fusion protein of GST and PC1-p30. Cells were lysed in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% TX-100, 5 mM DTT, PMSF, and protease inhibitor cocktail (Sigma). Lysates were agitated at 4°C for 30 min and precleared with CL-2B Sepharose. Cleared lysates were precipitated with glutathione Sepharose. After extensive washing precipitates were analyzed by immuno-blot with the indicated antibodies.

**Immuno blotting**
Cells were lysed on ice with SDS containing lysis buffer, boiled and used immediately or stored at -80°C. Tissues were chopped on dry ice, transferred to SDS buffer containing protease and phosphatase inhibitors (Sigma), sonicated, boiled and centrifuged. Protein concentration was measured by reading absorbance at 280 nm. Protein concentrations were normalized by addition of SDS lysis buffer containing glycerol, bromophenol blue and DTT. Proteins were separated by SDS-PAGE, transferred to PVDF membranes and probed with the indicated antibodies.
Plasmids
cDNAs of membrane-anchored and soluble PC1 constructs cloned into pCDNA4/TO (Invitrogen) have been described previously. Additional deletion and point mutations of PC1 constructs were made by PCR and/or site directed mutagenesis (Stratagene). Full-length wild-type PC1 was a gift from Gregory Germino (NIDDK, Bethesda). The STAT1/3 luciferase reporter containing 4 gamma interferon activation site (GAS) elements upstream of the luciferase gene was a gift from Tom Hamilton (Cleveland Clinic). Native human STAT3 and SOCS3 promoter regions fused upstream of a luciferase reporter gene were gifts from George Stark (Cleveland Clinic). EGFR plasmid was a gift from Deric Wheeler (University of Wisconsin). Wild type c-Src plasmid (Addgene plasmid 13663) was obtained from Joan Brugge (Harvard Medical School). Kinase dead (K297M), dominant negative (K297M Y529F), constitutively active (Y529F), SH2-binding (R175K), and SH3-binding (D99N) mutants of Src were all made on the same pCMV5 backbone using site directed mutagenesis. The SOCS3 plasmid (Addgene plasmid 11486) was obtained from Ronald Kahn (Harvard Medical School).

Antibodies and reagents
Src, total STAT3, pY-STAT3 (Tyr705), total JAK2 and pY-JAK2 (Tyr1007/1008) antibodies were from Cell Signaling Technology; β-actin antibody and PP2 from Sigma; Pan-14-3-3 antibody (K19) from Santa Cruz. IL6 and EGF were purchased from R&D Systems. Forskolin and pan Jak inhibitor (Pyridone 6) were purchased from Calbiochem. Forskolin was used at 10μM unless otherwise indicated. dDAVP was purchased from Bachem, Switzerland or Sigma. OPC31260 was provided by Otsuka.

Cell culture
MDCK cells were cultured as described. mpCkCD-cl11 cells were seeded on Transwell membranes and cultured as previously described with some modifications. After reaching confluency, cells were withdrawn from all hormone supplements and exposed to dDAVP (10^-9 M) added to the basolateral medium for 16h. dDAVP was withdrawn for 8h. PP2 (20 µM, diluted in DMSO) or vehicle was added both to the apical and basal medium for 12h. Cells were exposed to dDAVP (5min, 10-9M) added to the basolateral side of the cells. Appropriate vehicle controls were performed. Cells were lysed and analyzed by immunoblotting.

Rodent models
Animal studies were approved by the Institutional Animal Care and Use Committees and adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The bpk and Pkd1cond/cond:NestinCre mouse models have been described previously. Bpk mice and littermate controls were euthanized at postnatal day 21. Pkd1cond/cond:NestinCre mice and littermate controls were euthanized at postnatal day 180. PCK/Brattleboro rats were generated by breeding F1 rats resulting from PCK (Pkhd1/−/−) and Brattleboro (AVP−/−) crosses. PCK rats are homozygous for a splicing mutation (IVS35-2A→T) that skips exon 36 and leads to a frame shift in Pkhd1. Brattleboro rats lack circulating AVP and are homozygous for a 1-bp deletion of a guanine nucleotide in the second exon of the AVP gene that results in a frame shift of the coding sequence for the carrier neurophysin II. OPC31260 was administered to rats or mice as previously described by adding to ground chow (Purina labdiet 5053) at a concentration of 0.1% between three and ten weeks of age for rats, or 0.05% between 3 and 16 weeks of age for mice. dDAVP was administered to rats via osmotic minipumps (Alzet, CA) at a dose of 10ng/hr/100g body weight between 3 and 10 weeks of age.

Immunohistochemistry
Specimens were fixed in 10% formalin, embedded in paraffin, and 5µm sections were cut. Paraffin slides were deparaffinized with xylene and rehydrated with ethanol followed by antigen
retrieval in Target Retrieval Solution (DAKO) using a pressure cooker (Biocare Medical, Concord, Calif.). Sections were incubated with 3% hydrogen peroxide for 10 minutes to block endogenous peroxidase activity followed by 10% normal goat serum (Vector Laboratories) for 1 hour at room temperature. Primary antibodies were applied at 4°C overnight and then incubated with biotinylated secondary antibodies (Vector Laboratories) for 1 hour at room temperature. Avidin/streptavidin based detection system (Vectastain Elite ABC kit; Vector Laboratories) was used. The slides were developed using diaminobenzidine (Vector Laboratories) as substrate and counterstained with Mayer’s hematoxylin.

Supplemental Figure Legends

Supplemental Fig. 1
MDCK cells were cultured under minimal serum conditions (0.5% FBS) for the indicated periods of time resulting in increasing confluence, full confluence and further compacting post-confluence. The phase-contrast images correspond to representative fields of cells used in Fig. 1A.

Supplemental Fig. 2
Diagram of PC1 expression constructs used in this study. Relevant tyrosine residues and the PXXP motif are indicated.

Supplemental Fig. 3
Luciferase assay using HEK293T cells transfected with the STAT1/3 luciferase reporter and indicated genes. While PC1-p30 strongly increases Src-dependent activation of STAT3, the N- or C-terminal halves (NTp15 or CTp15, respectively) of PC1-P30 independently do not activate Src.

Supplemental Fig. 4
Luciferase assay using HEK293T cells transfected with the STAT1/3 luciferase reporter and indicated genes. ADPKD patient mutations within PC1-p30 do not disrupt the ability of the soluble PC1 tail to activate Src/STAT3.

Supplemental Fig. 5
Model of Src highlighting its important regulatory residues. Src can be activated by relieving two separate auto-inhibitory mechanisms 38: phosphorylation of Tyr529 leads to an intramolecular interaction with Src’s SH2 domain, and the adoption of a closed, inactive conformation. Phosphatases such as CSK1 dephosphorylate Tyr529 and initiate the Src activation process. Similarly, Src’s SH3 domain can undergo an intramolecular interaction that suppresses its enzymatic activity. Binding of proteins containing PXXP consensus motifs to the SH3 domain of Src can open the intramolecular interaction leading to kinase activation. The Src(R175K) mutant which has a significantly reduced ability to bind phosphotyrosyl-containing proteins to the Src SH2 domain 40.

Supplemental Fig. 6
A-B, native STAT3 (A) or native SOCS3 promoters (B) fused to a luciferase reporter gene transfected into HEK293T cells in combination with Src and PC1-p30. While Src and PC1-P30 do not independently induce the the STAT3 or SOCS3 promoters, PC1-p30 combined with Src
does.
Supplemental Fig. 4

![Supplemental Fig. 4 Image]

- Y-axis: Mean Fold Difference
- +Src
A) pSTAT3-Luc in 293T

B) pSOCS3-Luc in 293T